Case report: Incidental MALT lymphoma of the left adrenal gland mimicking a metastatic spread within durvalumab maintenance treatment in inoperable stage III non-small cell lung cancer

Lukas Käsmann; Esra Degerli; Karim El-Marouk; Farkhad Manapov

doi:10.3389/fonc.2024.1226422

Case report: Incidental MALT lymphoma of the left adrenal gland mimicking a metastatic spread within durvalumab maintenance treatment in inoperable stage III non-small cell lung cancer

Front Oncol. 2024 Mar 19:14:1226422. doi: 10.3389/fonc.2024.1226422. eCollection 2024.

Authors

Lukas Käsmann^{1

2

3}, Esra Degerli¹, Karim El-Marouk¹, Farkhad Manapov^{1

4}

Affiliations

¹ Department of Radiation Oncology, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, Germany.
² German Center for Lung Research (DZL), Partner Site Munich, Munich, Germany.
³ German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany.
⁴ Private Practise ´Die RADIOLOGIE´, Munich, Germany.

Abstract

Durvalumab after chemotherapy in non-operable stage III non-small cell lung cancer (NSCLC) is the standard of care worldwide. We present a patient with the incidental discovery of a unilateral MALT lymphoma of the adrenal gland and adrenalitis during durvalumab maintenance treatment detected by 18F-FDG-PET/CT. We assessed the clinical and histopathological findings, radiological examinations and overall treatment. Our work emphasizes the significance of considering other differential diagnoses and the importance of multidisciplinary treatment of the findings, especially within clinical trials.

Keywords: MALT lymphoma; NSCLC; PET/CT; durvalumab; immune-related side effect.

Publication types

Case Reports